Picture of BioNTech SE logo

BNTX BioNTech SE Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapSuper Stock

Annual income statement for BioNTech SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSPROSPECTUS20-F20-F20-F
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue61.612810948218,977
Cost of Revenue
Gross Profit52.311491.242316,065
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses1231812905653,693
Operating Profit-61.3-53.9-182-82.415,284
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-85.9-47.7-179-14615,046
Provision for Income Taxes
Net Income After Taxes-86-48.3-17915.210,293
Minority Interest
Net Income Before Extraordinary Items
Net Income-85.7-48-17915.210,293
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-85.7-48-17915.210,293
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.378-0.212-0.850.0639.3

Or unlock with your email

Or unlock with your email